We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
How to use a multiphase optimisation strategy (MOST) to evaluate your digital health product.
Advice for medical professionals to follow when assessing drivers with neurological disorders.
Covering thalidomide, lenalidomide, and pomalidomide: temporary guidance for pregnancy prevention arrangements for patients taking them during COVID-19
Public Assessment Report (PAR) discussing new risk minimisation measures which are being put into place for certain over-the-counter (OTC) stimulant laxatives.
Product Safety Report for TiaTio Concentrated Serum presenting a serious chemical risk
Product Safety Report for PTS Packers and Providers Pvt Surfaz-SN Triple Action Cream presenting a serious chemical risk.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).